MedTrace Logo

Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye

NCT00621439 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2013-12-02

No results posted yet for this study

Summary

The purpose of this study is to explore whether the drug pegylated-interferon-alfa-2b (PEG-IFN) has any effect on a certain type of immune cell (called natural killer cells) in patients with eye melanoma.

Conditions

  • Ocular Melanoma

Interventions

DRUG

Pegylated Interfon Alpha 2B

Patients will receive PEG-IFN 6 mcg/kg subcutaneously 4 days prior to surgery. Patients will be premedicated with acetaminophen 700 mb orally prior to the injection. Only one dose of drug will be given. Enucleation will follow in 4 days.

DRUG

Placebo

Patients will receive placebo.

Sponsors & Collaborators

  • Emory University

    lead OTHER

Principal Investigators

  • Hans Grossniklaus, MD · Emory University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2008-06-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00621439 on ClinicalTrials.gov